Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Adrafinil | Fasoracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication) | 20-100 mg 1-3 times daily (sublingual or oral) |
| Timing | Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration. | Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food. |
| Cycle Duration | Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring. | Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).
300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)
Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.
Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.
Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.
20-100 mg 1-3 times daily (sublingual or oral)
Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →